{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-009807","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2024-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.929376+00:00","generated_at":"2026-06-05T00:33:34.050130+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ovid Therapeutics reports Q4 2023 financial results and pipeline updates; soticlestat Phase 3 enrollment complete","bullets":["Soticlestat Phase 3 trials for Lennox-Gastaut and Dravet syndromes completed enrollment; Takeda expects topline data by September 2024.","Cash and marketable securities of $105.8M as of Dec 31, 2023; expected runway into first half of 2026.","OV888 (GV101) Phase 1 multiple-ascending dose study progressing; no serious adverse events; higher dose cohort added.","Net loss of $52.3M for full year 2023 compared to $54.2M in 2022; basic net loss per share $0.74.","Ovid retains 87% interest in soticlestat milestones and royalties; potential payments up to $660M plus low double-digit royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-009807","json":"https://secwatch.observer/filing/0001628280-24-009807.json","markdown":"https://secwatch.observer/filing/0001628280-24-009807.md","text":"https://secwatch.observer/filing/0001628280-24-009807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828024009807/0001628280-24-009807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828024009807/ovid-20240308.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:33:34.050130+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"996541f7d10f2898f122aaef9a089b062bbaf9bd","claim":"Ovid Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Business Update, Fourth Quarter and Full Year 2023 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000162828024009807/0001628280-24-009807-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}